Domov › Rak dojke › Nebraska › Omaha
Klinične študije za Rak dojke v Omaha, NE
22 študij za Rak dojke išče udeležence na lokacijah v Omaha in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.
Uradno besedilo študije (angleško)
Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Vključevanje udeležencevFaza 3
- Nebraska Cancer Specialists, Omaha
Phase IIIb Study of Ribociclib + ET in Early Breast Cancer
Vključevanje udeležencevFaza 3
- Nebraska Cancer Specialists, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
A Study of Dato-DXd in Inoperable or Metastatic Hormone Receptor-positive, HER2 IHC 0 Breast Cancer
Vključevanje udeležencevFaza 3
- Research Site, Omaha
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
Vključevanje udeležencevFaza 2
- Nebraska Cancer Specialists, Omaha
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
Vključevanje udeležencevFaza 2
- Oncology Hematology West, Pc Dba Nebraska Cancer Specialists, Omaha
ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer
Vključevanje udeležencevFaza 3
- Paradigm Oncology Hematology West P.C. dba Nebraska Cancer Specialists, Omaha
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
Vključevanje udeležencevFaza 1/2
- Nebraska Cancer Specialists, Omaha
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Vključevanje udeležencevFaza 3
- Oncology Hematology West, PC dba Nebraska Cancer Specialists - Legacy, Omaha
- University of Nebraska Medical Center, Omaha
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Vključevanje udeležencevFaza 3
- Nebraska Cancer Specialists, Omaha
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Vključevanje udeležencevFaza 3
- Nebraska Cancer Specialists, Omaha
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Vključevanje udeležencevFaza 3
- Nebraska Medicine-Village Pointe, Omaha
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- in še 3
Study of [177Lu]Lu-DWJ155 and [68Ga]Ga-DWJ155 in Patients With Solid Tumors
Vključevanje udeležencevFaza 1
- Nebraska Cancer Specialists, Omaha
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
Vključevanje udeležencevFaza 3
- Nebraska Cancer Specialists, Omaha
- Nebraska Medicine - University of Nebraska Medical Center, Omaha
A Study to Assess the Efficacy and Safety of FORE8394 in Participants With Cancer Harboring BRAF Alterations
Vključevanje udeležencevFaza 2
- Nebraska Cancer Specialists - Midwest Cancer Center - Legacy, Omaha
Integrated Cancer Repository for Cancer Research
Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
- Methodist Estabrook Cancer Center, Omaha
- Nebraska Methodist Health System, Omaha
- University of Nebraska Medical Center, Omaha
- in še 1
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Vključevanje udeležencevFaza 1
- Nebraska Cancer Specialists (Midwest Cancer Center - Legacy), Omaha
- XCancer Omaha / Urology Cancer Center, Omaha
ERAS Protocols in Breast Conserving Surgery
Vključevanje udeležencev
- University of Nebraska Medical Center, Omaha
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Vključevanje udeležencevFaza 3
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi stran
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Vključevanje udeležencevOpazovalna študija
- Massive Bio SYNERGY-AI site, Omaha
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
Vključevanje udeležencevFaza 1
- Biotheryx Investigative Site, Omaha
CtDNA Based MRD Testing for NAC Monitoring in TNBC
Vključevanje udeležencevOpazovalna študija
- Nebraska Methodist, Omaha
Študije za Rak dojke v drugih mestih
- New York City, NY136 študij
- Houston, TX126 študij
- Boston, MA112 študij
- Nashville, TN81 študij
- Los Angeles, CA73 študij
- Edison, NJ68 študij
- St. Louis, MO64 študij
- Queens, NY64 študij
- Durham, NC64 študij
- Chicago, IL59 študij
- Philadelphia, PA56 študij
- Dallas, TX55 študij
Druge študije v Omaha
- Rak prostate27 študij
- Nemalicelični pljučni rak24 študij
- Rak (vse vrste)18 študij
- Kolorektalni rak18 študij
- Množni mielom16 študij
- Rak jajčnikov14 študij
- Non-Hodgkinov limfom14 študij
- Rak trebušne slinavke14 študij
- Metastatski rak13 študij
- Ploščatocelični karcinom glave in vratu13 študij
- Srčno popuščanje13 študij
- Melanom12 študij
Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.